

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

FLA-0035

U.S. APPLICATION NO. 09/486266

INTERNATIONAL APPLICATION NO.
PCT/EP98/05321INTERNATIONAL FILING DATE
21 August 1998PRIORITY DATE CLAIMED
5 September 1997

TITLE OF INVENTION

TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A RESERVOIR-TYPE PRESSURE-SENSITIVE
ADHESIVE LAYER AND A BACK LAYER WITH UNI-DIRECTIONAL RESILIENCE

APPLICANT(S) FOR DO/EO/US

HILLE, Thomas and DEURER, Lothar

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2))
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

Return Post Card

"Express Mail" Label No. @EL476650364US
Date of Deposit 22 February 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492(a)(1) - (5)) : 09/486266	INTERNATIONAL APPLICATION NO PCT/EP98/05321	ATTORNEY'S DOCKET NUMBER FLA-0035
---	---	---

21. The following fees are submitted.:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$970.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$840.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$670.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **\$96.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$840.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	36 - 20 =	16	x \$18.00
Independent claims	1 - 3 =	0	x \$78.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>

\$288.00**\$0.00****\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,128.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☐**\$0.00****SUBTOTAL =****\$1,128.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00**TOTAL NATIONAL FEE =****\$1,128.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☐**\$0.00****TOTAL FEES ENCLOSED =****\$1,128.00**

Amount to be refunded	\$
charged	\$

☒ A check in the amount of **\$1,128.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1086** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata

Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515
Facsimile : (856) 810-1454

Jane Massey Licata
SIGNATURE

LICATA, Jane Massey

NAME

32,257

REGISTRATION NUMBER

22 February 2000

DATE

09/486266

430 Rec'd PCT/PTO 22 FEB 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: FLA-0035

Inventors: HILLE AND DEURER

International

Application No.: PCT/EP98/05321

U.S. Serial No.: N/A

International

Filing Date: AUGUST 21, 1998

U.S. Filing Date: HERewith

Title: TRANSDERMAL THERAPEUTIC SYSTEM
COMPRISING A RESERVOIR-TYPE PRESSURE-
SENSITIVE ADHESIVE LAYER AND A BACK
LAYER WITH UNI-DIRECTIONAL RESILIENCE

"Express Mail" Label No. EL476659364US
Date of Deposit: 22 February 2000

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents, Box PCT,
Washington, D.C. 20231.

By Deborah Ehret
Typed Name: DEBORAH EHRET

Assistant Commissioner for
Patents
Box PCT
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

Please amend the above-referenced application as follows:

006050" 343460

26. The transdermal therapeutic system of claim 22 wherein the elasticity of the backing layer is less than 150%.

27. The transdermal therapeutic system of claim 22 wherein the backing layer projects beyond the reservoir layer on all sides.

28. The transdermal therapeutic system of claim 23 further comprising a separating layer between the reservoir layer and the backing layer.

29. The transdermal therapeutic system of claim 22 wherein the elastic material of the backing layer has an elasticity of between 20-80%.

30. The transdermal therapeutic system of claim 29 wherein the elastic material of the backing layer has an elasticity of between 40-70%.

31. The transdermal therapeutic system of claim 30 wherein the elastic material of the backing layer has an elasticity of between 44-56%.

33. The transdermal therapeutic system of claim 32 wherein the material comprising the backing layer is more than 99% microbially nondegradable.

34. The transdermal therapeutic system of claim 22 wherein the backing layer comprises a woven fabric, a nonwoven fabric or a film.

35. The transdermal therapeutic system of claim 22 wherein the backing layer comprises a material selected from the group consisting of a polyethylene, a polypropylene and a polyester.

36. The transdermal therapeutic system of claim 35 wherein the backing layer comprises a polyalkylene terephthalate.

37. The transdermal therapeutic system of claim 36 wherein the backing material is a polyterephthalic diester.

38. The transdermal therapeutic system of claim 37 wherein the backing material is a polyterephthalic acid diol ester obtainable by the reaction of a starting material selected from ethylene glycol, 1,4-butanediol, 1,4-dihydroxymethylcyclohexane, terephthalic acid, isophthalic acid, adipic acid, azelaic acid, sebacic acid, dimethyl terephthalate, dimethyl azelate, dimethyl sebacate, bisphenol A diglycidyl ether, n-decane-1,10-dicarboxylic acid, polyethylene glycol and polybutylene glycol.

39. The transdermal therapeutic system of claim 22 wherein the reservoir layer comprises at least one active substance selected from the group consisting of a psychopharmaceutical, an analgesic and a hormone.

40. The transdermal therapeutic system of claim 39 wherein the active ingredient is oestriol, buprenorphine or a parasympathomimetic.

41. The transdermal therapeutic system of claim 22 wherein the reservoir layer contains a water-absorbing polymer.

42. The transdermal therapeutic system of claim 41 wherein the water-absorbing polymer is a polyvinylpyrrolidone.

43. The transdermal therapeutic system of claim 42 wherein the polyvinylpyrrolidone has a molecular weight in the range of 1×10^3 to 2×10^6 .

44. The transdermal therapeutic system of claim 22 wherein the backing layer which faces outwards has a differentiated marking element.

45. The transdermal therapeutic system of claim 44 wherein the marking element is a colored marking.

46. The transdermal therapeutic system of claim 45 wherein the colored marking is in strip form or a colored thread.

47. The transdermal therapeutic system of claim 44 wherein the marking element has an elasticity of between -20% to +20% relative to the elasticity of the remaining portion of the backing layer.

54. A method of treating pain or drug dependency comprising administering an active substance in the transdermal therapeutic system of claim 22.

55. A method of treating pain or drug dependency comprising administering an active substance in the transdermal therapeutic system of claim 39.

56. A method of treating pain or drug dependency comprising administering an active substance in the transdermal therapeutic system of claim 40.

57. A method of producing the transdermal therapeutic system of claim 22 comprising the steps of inserting pressure-sensitive adhesive substance reservoir sections in a sequence in the longitudinal direction into a presupplied strip-like laminate comprising a redetachable protective layer and a backing layer

48. The transdermal therapeutic system of claim 22 wherein the backing layer has a water vapor permeability of at least 0.1 g/m²/h.

49. The transdermal therapeutic system of claim 48 wherein the backing layer has a water vapor permeability of between 1 to 20 g/m²/h.

50. The transdermal therapeutic system of claim 22 comprising pores wherein the areal proportion of pores having a size of $\leq 400 \text{ um}^2$ is between 10% to 50%.

51. The transdermal therapeutic system of claim 22 wherein the backing layer has a number of warp threads in the range from 300 to 350 per 10 cm of unextended fabric and a number of weft threads in the range from 100 to 140 per 10 cm of unextended fabric.

52. The transdermal therapeutic system of claim 51 wherein the number of weft threads is in the range from 120 to 130.

Preliminary Amendment
PCT/EP98/05321
Attorney Docket No: FLA-0035
Page 9

comprising a unidirectional backing material; separating the backing layer by punching; removing the unwanted cut portion of the backing layers; and separating the protective layer in the space between the active substance reservoir sections.--

REMARKS

The pending claims in PCT/EP98/05321 have been canceled and replaced with new claims to conform to U.S. practice for entry into National Phase. No new matter has been added by these amendments.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: 22 February 2000

Law Offices of
JANE MASSEY LICATA
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

11 PRT

09/486266
430 Rec'd PCT/PTO 22 FEB 2000

TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING A RESERVOIR-TYPE
PRESSURE-SENSITIVE ADHESIVE LAYER AND A BACK LAYER WITH
UNI-DIRECTIONAL RESILIENCE

The invention relates to a transdermal therapeutic system, in particular an active substance patch, comprising a redetachable protective layer, a pressure-sensitive reservoir layer and a backing layer with or without a coating of pressure-sensitive adhesive. The invention also relates to a process for producing such a transdermal therapeutic system [occasionally abbreviated to TTS below] and to the use thereof.

A TTS is a skin-applied administration form for active substances for delivery through the skin, and has the appearance of traditional patches. It ought to be distinguished from a topical active substance plaster - for example, a rheumatism plaster or a corn plaster. A TTS of this kind can include one or more active substances which are delivered continuously over a fixed period at a predetermined rate to the site of application ("Heilmann, Klaus: Therapeutische Systeme - Konzept und Realisation programmierter Arzneiverabreichung" [Therapeutic systems - design and implementation of programmed drug administration], 4th edition, 1984, Ferdinand-Enke-Verlag, Stuttgart). The fixed period referred to above is usually 24 hours. For the treatment of chronic disorders, however, it is necessary to administer medicaments for a longer period. It may therefore be appropriate to apply a TTS for a period longer than 24 hours, since this is more likely to result in constant plasma levels.

A typical such transdermal therapeutic system in the form of a patch is known from EP-B 0 430 019. It has a backing layer which is impermeable to the active substance, a

000050 " 09298450

pressure-sensitive adhesive reservoir layer, and a redetachable protective layer. The active-substance-impermeable backing layer can be composed of flexible or inflexible material. Substances which it is mentioned are used for producing such materials are polymer films or metal foils or else a composite comprising a film which has been coated with aluminium by vapour deposition. Where such systems are worn on the skin for a prolonged period, as is necessary (as mentioned above) for treating chronic disorders in particular, a pronounced sensation of a foreign body is perceived on the skin within a short time, owing to the relative rigidity of the TTS. This is extremely unpleasant for the user.

Another embodiment of such a TTS is described in US-A 5,246,705. The transdermal system it describes has an elastomeric backing layer having a defined vapour transmission rate in the range from 0.1 to 20 g/m²/hr and a Young's modulus in the range of about 10⁴ to 10⁹ dynes/cm². Particularly preferred materials for the elastomeric backing layer are, for example, A-B-A block copolymers, the A blocks comprising styrene and the B blocks saturated hydrocarbon polymers such as, for instance, ethylene-butylene copolymers, ethylene-propylene copolymers, and the like. When the transdermal therapeutic systems as per the said US-A 5,246,705 are worn on the skin for a prolonged period, again, it is impossible to avoid the above-described sensation of a foreign body.

US-A 4,780,168 discloses a strip-like wound bandage for sealing wounds, which is fabricated from a woven or non-woven, polymer-based material, the said material having a planar stretching characteristic in the range from 0.5 to 110 [pounds/inch]. Materials of such extensibility are, however, not immediately suitable as materials for backing

layers of transdermal therapeutic systems. Either their extensibility is too low, in which case the unpleasant foreign-body sensation described above is felt when they are worn on the skin for a prolonged period, or else they are much too extensible, in which case the production of transdermal therapeutic systems is accompanied by the so-called curling effect, which is explained below.

During the production of the laminate from which the individual active substance patches are punched, the material for the backing layer comes under tensile stress and the resulting elastic return force means that, during punching, the opposite ends of the patches are each bent up. Owing to the reject rate during manufacture, this effect results in high costs, together with unnecessary environmental burden.

Aside from the abovementioned disadvantages, a material for the backing layer of a wound bandage is also unsuited to a TTS for other reasons too, such as the required impermeability to active substance.

The object of the invention is therefore to provide a transdermal therapeutic system which comprises a redetachable protective layer, a pressure-sensitive adhesive reservoir layer and a backing layer with or without a coating of pressure-sensitive adhesive and which avoids the aforementioned disadvantages. In particular, there should be no sensation of a foreign body on the skin in the course of prolonged wearing, even for periods of from several days to about 1 or 2 weeks. Furthermore, the production of the TTS should not be accompanied by the curling effect, so ensuring rational and inexpensive production.

Preferred embodiments of the TTS of the invention are subject-matter of the dependent claims.

In accordance with the invention, the TTS features not only a redetachable protective layer and a pressure-sensitive adhesive reservoir layer but also a backing layer which, optionally, is likewise coated with pressure-sensitive adhesive and which has a specifically defined unidirectional elasticity. With regard to the TTS of the invention, the elasticity is determined in accordance with the DIN standards 60 000 and 61 632 (April 1985), which are conventionally used for elasticity tests. Originally, these DIN standards do in fact apply to ideal bandages; the horizontal force extension unit used to test the elasticity can, however, be employed analogously for other materials as well. In accordance with the invention, the backing layer of the TTS is elastic in only one direction, i.e. in longitudinal or transverse direction. Relative to the longitudinal axis of the TTS, the transverse axis is that lying at right angles to it. In a circular TTS, the longitudinal and transverse axis are of course identical in length. In particular, the backing layer material used in accordance with the invention is unidirectionally longitudinally elastic.

In the other direction, the backing layer is nonelastic. Nonelastic means that no elasticity can be found when testing by hand. In the case of measurement in accordance with DIN 61 632, then, the elasticity is less than 20%. In accordance with the invention, therefore, the elasticity in one direction - mainly the elastic direction - is above 20%.

Since the production of the patch involves it being punched out from a laminate, it would also be possible to conceive in principle of the TTS being "unidirectionally" elastic at an angle to the longitudinal direction of the patch. Oblique elasticity of this kind is, however, the result of a superposition of elasticity in the transverse and longitudinal directions.

In the TTS of the invention, the elasticity of the unidirectionally elastic material used for the backing layer is preferably less than 150%. In a more preferred embodiment the elasticity is in the range from 20 to 80%, with particular preference in the range from 40 to 70%. The most preferred elasticity for a backing layer material, and, accordingly, that which is most advantageous for the achievement of the object on which the invention is based, lies within the range between 44 and 56%, always measured in accordance with DIN 61 632.

Preferred materials for the unidirectionally elastic backing layer are those which are microbially nondegradable. The material should be more than 90%, preferably more than 99%, microbially nondegradable. The degradability can be measured by conventional methods familiar to the person skilled in the art. Low degradability is particularly important in the case of TTSS which are to be worn on the skin for a prolonged period.

The reason for this is that, owing to the transpiration of the skin, a microclimate in which bacteria, fungi, spores etc. absolutely thrive develops directly below the section of skin covered by the TTS. Consequently, low microbial degradability, especially in the case of prolonged wearing, is extremely advantageous. The material of the backing layer can be a woven fabric, a nonwoven fabric or a film. Where the backing layer comprises a polymer, the said polymer is selected advantageously from polyethylene, polypropylene or polyesters, especially polyalkylene terephthalates.

A number of polymeric materials may be mentioned by way of example for the backing layer. Advantageous polymeric materials which meet the above requirement of low microbial degradability are polyterephthalic diesters obtainable by the reaction of a starting material selected from ethylene glycol, 1,4-butanediol, 1,4-dihydroxymethylcyclohexane, terephthalic acid, isophthalic acid, adipic acid, azelaic acid, sebacic acid, dimethyl terephthalate, dimethyl azelate, dimethyl sebacate, bisphenol A diglycidyl ether, n-decane-1,10-dicarboxylic acid, polyethylene glycol and polybutylene glycol.

In the transdermal therapeutic system of the invention, it is likewise possible for a further separating layer to be arranged between backing layer and reservoir layer for the purpose, for example, of preventing active substance permeability. In this case, the backing layer on the skin-facing side, and/or the separating layer on the distal side, are/is likewise coated with pressure-sensitive adhesive.

For the effectiveness of a TTS of the invention it is advantageous for the backing layer to project beyond the

reservoir on all sides. This has the advantage that there are no losses of active substance in the lateral direction. Furthermore, the TTS of the invention can be produced in a particularly inexpensive manner in this case, since the sections containing active substance can be punched separately. This avoids expensive, environmentally harmful, leftover waste pieces containing active substance. The backing layer of the TTS has a water vapour permeability of at least $0.1 \text{ g/m}^2/\text{h}$, preferably from 1 to $20 \text{ g/m}^2/\text{h}$.

Where a woven or nonwoven fabric or else a porous film is used, the porosity lies within the range from 10% to 50%. Porosity here means the proportion of pores having an area of $\leq 400 \text{ } \mu\text{m}^2$ as a percentage of the reference area in question. This relative pore area can be determined by measuring and counting the pores of any unextended reference area under the microscope or a thread counter.

If a woven fabric is used for the transdermal therapeutic system (TTS) of the invention, the backing layer has a number of warp threads in the range of 300-350, preferably in the range of 310-330, and/or a number of weft threads in the range from 100 to 140, preferably in the range from 120 to 130, measured in each case per 10 cm of unextended fabric.

The pressure-sensitive adhesive reservoir layer of the transdermal therapeutic system of the invention comprises at least one active substance. This substance is preferably selected from the group consisting of psychopharmaceuticals, analgesics and hormones. Particular substances which may be considered include estradiol as a hormone and buprenorphine as an analgesic. The psychopharmaceutical is preferably a parasympathomimetic.

Particularly suitable parasympathomimetics are the following:

1. choline esters, e.g. acetylcholine, bethanechol, carbachol or methacholine;
2. alkaloids, e.g. arecoline and its derivatives, pilocarpine;
3. choline esterase inhibitors, e.g. demacarium bromide, distigmine bromide, neostigmine, physostigmine, pyridostigmine bromide, galanthamine.

These substances can of course also be used in combinations with one another. The active substance content is set in particular such that when the plaster is removed there is what is known as a pulloff effect. This effect is explained hereinbelow:

Where a TTS includes a backing layer of limited water vapour permeability, such as a PET film, the skin is unable to give off water vapour at the application site while the TTS is being worn. This water becomes incorporated in the skin. At the application site, therefore, the water content is higher than the physiobiological norm. A substance which is difficult for the skin to absorb (such as buprenorphine, for example) becomes incorporated into a deposit in the skin. When the TTS is pulled off, the skin gives off water vapour suddenly. As a result of removal of this water, there is a sudden increase in the concentration of the medicament to above the saturation concentration, since solvent is removed. A stable state is reached by the rapid emptying of the skin deposit. Therefore, as a result of the TTS being pulled off, there is a rapid increase in the plasma concentration of the active substance. The utilization of the pulloff effect is preferred for better utilization of active substance. In accordance with the

invention, therefore, the concentration of the active substance is set such that the abovementioned pulloff effect comes about.

The absolute level of active substance for achieving the pulloff effect cannot generally be defined validly with precision. It varies from one active substance to another and also depends on the embodiment of the TTS. Setting of the level can, however, be undertaken by the person skilled in the art without undue burden by means of routine experiments. In the case of buprenorphine, the level is about 5 - 15% by weight.

The pressure-sensitive adhesive reservoir layer may also include a water-absorbing polymer. In one preferred embodiment, the water-absorbing polymer is a polyvinylpyrrolidone. The polyvinylpyrrolidone preferably has a molecular weight in the range from 1×10^3 to 2×10^6 . Such polyvinylpyrrolidones include Kollidon®.

For special purposes, moreover, such as for use in hospitals with many patients or for use in double blind studies where TTS containing active substance are compared with placebo TTS, it is preferred for the side of the TTS that faces outwards - that is, away from the skin - to carry in the backing layer a marking/control element which is differentiated from the remaining area.

This element can differ from the remaining portion of the backing layer in its structure or in other properties, such as elasticity or porosity. By means of such a marking/control element the properties of the backing layer can be made different. For example, the elasticity of such an element can be greater than the elasticity of the remaining portion of the backing layer. If such a

marking/control element is specifically incorporated in one portion of the backing layer, then its relative elasticity - where desired - is preferably within a range situated about 20% below or about 20% above the elasticity of the remaining portion of the backing layer.

The marking/control element can also serve to distinguish the individual TTSs from one another in terms of their active substance content. This is done preferably by means of coloured marking, for example by means of a coloured thread or stripe. This is particularly advantageous if the TTS has to be held ready in large quantities at different dosages at one location: for example, a hospital with large numbers of patients.

The transdermal therapeutic system of the invention is particularly suitable for use as a multi-day plaster owing to its backing layer, which is tailored to this requirement. Thus it can be used in particular to treat chronic pain or else to treat drug dependency.

The TTS of the invention is produced by means of conventional processes. In general, such a process comprises the steps of producing the individual TTSs by punching from a presupplied strip-like laminate comprising the unidirectionally elastic backing layer of the invention, an active substance layer and a redetachable protective layer.

In one particularly preferred process for producing the TTS of the invention, the above steps are modified to the effect that, in a presupplied strip-like laminate having an optionally pressure-sensitive adhesive, unidirectionally elastic backing layer and a redetachable protective layer, pressure-sensitive adhesive active substance reservoir

sections are inserted in sequence in the longitudinal direction, the backing layer is separated by punching and then in the spaces between the active substance reservoir sections the protective layer is separated. This specific process has the feature that it is highly advantageous from both economic and environmental standpoints. Indeed, the separate insertion of the active substance reservoir sections avoids the formation of waste comprising active substance (which is usually very expensive) and thus the need to dispose - again at great expense - of such waste. A similar process is described in DE-B 41 10 027, which in this respect is expressly incorporated herein by reference.

The invention is elucidated below with reference to a drawing and an exemplary embodiment. In the figures,

Fig. 1 shows a plan view of the TTS of the invention;
Fig. 2 shows a section made at II-II through the TTS of Fig. 1.

Fig. 1 shows, diagrammatically, a plan view of a TTS of the invention. Lying atop the redetachable protective layer (1), which in the present case is rectangular, is the backing layer (5), which is coated with a pressure-sensitive adhesive devoid of active substance. It has the form of a rectangle with rounded corners. The punching line (1a) outlines the form of the backing layer (5). It extends outside the laminate comprising the reservoir (2) and, optionally, a barrier or separating layer (3). The course of the punching line means that loss of active substance is avoided when the patch is punched out. Within the backing layer (5) it is possible to make out the contours of the reservoir (2) and of the optional barrier layer (3).

Fig. 2 is a cross section through II-II of Fig. 1. For clarity, the thicknesses of the layers have been exaggerated. The TTS features the reservoir (2), the removable protective layer (1) and also the optional barrier layer (3) and a further layer (4) of pressure-sensitive adhesive devoid of active substance, this layer (4) being necessary when a barrier layer (3) is present. In this depicted embodiment, the backing layer (5) and the pressure-sensitive adhesive layer (4) devoid of active substance protrude beyond the abovementioned laminate on all sides.

Example

In order to produce the unidirectionally elastic backing layer of the invention, a woven polyester fabric having the following features was produced by means of the techniques known to the person skilled in the art.

TEST FEATURES	UNIT	Nominal	MIN	MAX	\bar{X}
WIDTH OF MATERIAL	mm	1500	1300	1390	1360
BASIS WEIGHT (unextended) (DIN 53854 + DIN 53884)	g/m ²	100	95	103	100
EXTENSION (longitudinal)	%	-	-	-	-
(transverse)	%	50	46	52	48
(DIN 61632)					
NUMBER OF WARP THREADS Per 10 cm unextended		320	310	330	324
NUMBER OF WEFT THREADS Per 10 cm unextended		125	124	126	124

In addition

49.175 kg of Durotak type 387-2054 (48.3% by weight solution)

4.450 kg of melted laevulinic acid and

6.675 kg of oleyl oleate

were homogenized with stirring. Then 4.450 kg of Kollidon 90F were added in portions. Following dilution with

6.800 kg of ethanol, the mixture was stirred at 170-190 rpm for 5 hours. Then 4.450 kg of buprenorphine base, suspended in 4.500 kg of ethyl acetate, were added. The mixture was diluted with 4.500 kg of ethyl acetate.

The mixture was stirred at 170 rpm for about 7 hours. It was then tested for homogeneity. When the composition was homogeneous it was devolatilized, with the stirrer switched off.

Following homogenization, the adhesive composition was applied to a siliconized polyester film. The organic solvents were removed by drying at normally 35°C to 80°C. The laminate, comprising siliconized polyester film and buprenorphine-containing pressure-sensitive adhesive layer, was subsequently covered with a second polyester film 23 μ m thick.

The siliconized polyester film was removed from the resulting active substance laminate. Subsequently, rectangles measuring 50 cm² were punched out and were placed with their adhering face, at intervals of 3 cm, onto the siliconized face of a further 100 μ m polyester protective film. Atop these reservoir sections was placed the unidirectionally elastic, woven polyester fabric, which in this case was likewise coated with pressure-sensitive adhesive. Subsequently, individual longitudinally elastic patches were punched out. A wearing test was conducted on n=10 subjects using this TTS of the invention.

Comparative Example 1

In this example, a bidirectionally elastic woven polyester fabric was used instead of the unidirectionally elastic woven polyester fabric of the invention. The extensibility of this fabric (longitudinal and transverse extension) was

30% as measured in accordance with DIN 61632. Its basis weight was 109 g/m². This material was a polyethylene terephthalate. In other respects, the TTSs produced in accordance with this comparative example were the same as those of the inventive example.

Using the TTSs according to this comparative example, a wear test was likewise conducted on n=10 subjects.

Comparative Example 2

TTSs were prepared in accordance with Example 1 and Comparative Example 1 but using a rigid polyester film (15 µm thick) of Hostaphan® RN 15, Hoechst AG, coated with pressure-sensitive adhesive, instead of a unidirectionally or bidirectionally elastic backing layer, respectively. In this case as well, a wear test was carried out with the resulting TTSs on n=10 subjects.

Evaluation

The comparative wear test of the TTSs of Example 1, Comparative Example 1 and Comparative Example 2 gave the following result:

When polyester film was used as the backing layer (Comparative Example 2), a sensation of a foreign body occurred on the very first day. On the second day, creasing occurred and, beginning on the third day, the TTS became detached. The TTS of Example 1 and that of Comparative Example 1 were worn without problems by all 10 subjects, with no sensation of a foreign body, with no impairment of bond strength, and, furthermore, with no skin irritations, for at least seven days. In respect of wear comfort, therefore, the TTS of Example 1 and that of Comparative Example 1 are approximately equal. However, with regard to the production of the TTS of Comparative Example 1,

[illegible]

Claims

1. Transdermal therapeutic system, in particular a patch, comprising
 - a redetachable protective layer,
 - a pressure-sensitive adhesive reservoir layer and
 - a backing layer with or without a coating of pressure-sensitive adhesive and featuring a unidirectionally, preferably longitudinally, elastic material having an elasticity of at least 20%.
2. Transdermal therapeutic system according to Claim 1, wherein the elasticity is less than 150%.
3. Transdermal therapeutic system according to Claim 1 or 2, wherein the backing layer projects beyond the reservoir on all sides.
4. Transdermal therapeutic system according to one of the preceding claims, wherein a separating layer is arranged between the reservoir layer and the backing layer coated with pressure-sensitive adhesive.
5. Transdermal therapeutic system according to one of the preceding claims, wherein the elastic material has an elasticity in the range 20-80%, with particular preference in the range 40-70%, most preferably in the range 44-56%.
6. Transdermal therapeutic system according to one of the preceding claims, wherein the material of the backing layer is more than 90%, preferably more than 99%, microbially nondegradable.

7. Transdermal therapeutic system according to one of the preceding claims, wherein the backing layer is a woven fabric, a nonwoven fabric or a film.
8. Transdermal therapeutic system according to one of the preceding claims, wherein the backing layer essentially comprises a material selected from the group consisting of polyethylenes, polypropylenes and polyesters, selected in particular from the polyalkylene terephthalates.
9. Transdermal therapeutic system according to Claim 8, wherein the material of the backing layer is a polyterephthalic diester, preferably a polyterephthalic acid diol ester obtainable by the reaction of a starting material selected from ethylene glycol, 1,4-butanediol, 1,4-dihydroxymethyl-cyclohexane, terephthalic acid, isophthalic acid, adipic acid, azelaic acid, sebacic acid, dimethyl terephthalate, dimethyl azelate, dimethyl sebacate, bisphenol A diglycidyl ether, n-decane-1,10-dicarboxylic acid, polyethylene glycol and polybutylene glycol.
10. Transdermal therapeutic system according to one of the preceding claims, wherein the pressure-sensitive adhesive reservoir layer comprises at least one active substance selected preferably from the group consisting of psychopharmaceuticals, analgesics and hormones.
11. Transdermal therapeutic system according to Claim 10, wherein the hormone is oestradiol, the analgesic is buprenorphine and the psychopharmaceutical is a parasympathomimetic.

12. Transdermal therapeutic system according to one of the preceding claims, wherein the pressure-sensitive adhesive reservoir layer contains a water-absorbing polymer.
13. Transdermal therapeutic system according to Claim 12, wherein the water-absorbing polymer is a polyvinylpyrrolidone, preferably one having a molecular weight in the range from 1×10^3 to 2×10^6 .
14. Transdermal therapeutic system according to one of the preceding claims, wherein the side of the backing layer which faces outwards has a marking/control element which is differentiated from the remaining area.
15. Transdermal therapeutic system according to Claim 14, where the marking/control element is a coloured marking, preferably in stripe form, or a coloured thread.
16. Transdermal therapeutic system according to one of Claims 14 and 15, wherein the marking/control element which has an elasticity in the range from -20% to +20% relative to the elasticity of the remaining portion of the backing layer.
17. Transdermal therapeutic system according to one of the previous claims, wherein the backing layer has a water vapour permeability of at least $0.1 \text{ g/m}^2/\text{h}$, preferably from 1 to $20 \text{ g/m}^2/\text{h}$.
18. Transdermal therapeutic system according to one of the preceding claims, wherein the areal proportion of

pores having a size of $\leq 400 \mu\text{m}^2$ is in the range from 10% to 50%.

19. Transdermal therapeutic system according to one of the previous claims, wherein the backing layer has a number of warp threads in the range from 300 to 350, preferably in the range from 310 to 330, and/or a number of weft threads in the range from 100 to 140, preferably in the range from 120 to 130, in each case per 10 cm of unextended fabric.
20. A process for producing the transdermal therapeutic system according to one of Claims 1 to 19, comprising the steps of
 - in a presupplied strip-like laminate having an optionally pressure-sensitive adhesive, unidirectionally elastic backing layer and a redetachable protective layer, inserting pressure-sensitive adhesive active substance reservoir sections in sequence in the longitudinal direction,
 - separating the backing layer by punching,
 - removing the unwanted cut portion of the backing layer and
 - then separating the protective layer in the spaces between the active substance reservoir sections.
21. Transdermal therapeutic system according to one of Claims 1 to 19 for use as a multi-day plaster, in particular for the treatment of pain or of drug dependency.


[illegible]

A transdermal therapeutic system (TTS), in particular a patch, is described, comprising

- a redetachable protective layer,
- a pressure-sensitive adhesive reservoir layer and
- a backing layer with or without a coating of pressure-sensitive adhesive and featuring a unidirectionally, preferably longitudinally, elastic material having an elasticity of at least 20%. The TTS is particularly suitable for use as a multi-day plaster, for the treatment, for instance, of pain or of drug dependency.



Fig. 2



COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **Transdermal Therapeutic System Comprising a Reservoir-Type Pressure-Sensitive Adhesive Layer and a Back Layer with Uni-Directional Resilience** the specification of which:

() is attached hereto.

(XX) was filed on 21 August 1998 as Application Serial No. PCT/EP98/05321 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed			
Germany	197 38 855.8	5 Sept. 1997	Yes	X	No	
			Yes		No	
			Yes		No	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **Jane Massey Licata**, Registration No. 32,257, **Kathleen A. Tyrrell**, Registration No. 38,350, and **Laura M. Plunkett**, Registration No. 45,015 of the firm of **Law Offices of Jane Massey Licata**, 66 East Main Street, Marlton, New Jersey 08053, and

Address all telephone calls and correspondence to:

Jane Massey Licata, Esq.

Law Offices of Jane Massey Licata

66 East Main Street

Marlton, New Jersey 08053

Telephone No.: (856) 810-1515

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

1-00

2.00

[illegible]